ANZTCT consensus position statement on ruxolitinib in steroid‐refractory acute and chronic graft‐versus‐host disease
Internal Medicine Journal · 2023
DOI: 10.1111/imj.16255 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2023. Verfasst von Nada Hamad und 11 weiteren Autor:innen. Beteiligte Einrichtung: St Vincent's Hospital Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Bronchiolitis Obliterans Syndrome, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharmaceuticals Australia Pty Limited, Novartis Australia.
Abstract (Originalsprache)
This position paper provides an overview of the assessment and management of both acute and chronic graft‐versus‐host disease (GvHD). There is a focus on the use of ruxolitinib, a selective inhibitor of Janus kinase (JAK)1 and JAK2, for the treatment of corticosteroid‐refractory and corticosteroid‐dependent GvHD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
- School of Clinical Medicine, UNSW Medicine & Health, Sydney, New South Wales, Australia.
- School of Medicine, Sydney University of Notre Dame, Sydney, New South Wales, Australia.
- Westmead Hospital, Sydney, New South Wales, Australia.
- Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Royal Melbourne Hospital, Melbourne, Victoria, Australia.
ORCID-Profile: Nada Hamad
Förderung
- Novartis Pharmaceuticals Australia Pty Limited
- Novartis Australia
Zitieren
APA
Hamad, N., Bilmon, I., Chee, L., Henden, A., Johnston, A., Purtill, D., Bajel, A., Tey, S. K., Yeung, D., Cole, T., Lewis, C., & Butler, J. (2023). ANZTCT consensus position statement on ruxolitinib in steroid‐refractory acute and chronic graft‐versus‐host disease. Internal Medicine Journal. https://doi.org/10.1111/imj.16255
Vancouver
Hamad N, Bilmon I, Chee L, Henden A, Johnston A, Purtill D, et al. ANZTCT consensus position statement on ruxolitinib in steroid‐refractory acute and chronic graft‐versus‐host disease. Internal Medicine Journal. 2023. doi:10.1111/imj.16255
BibTeX
@article{Hamad2023,
author = {Hamad, Nada and Bilmon, Ian and Chee, Lynette and Henden, Andrea and Johnston, Anna and Purtill, Duncan and Bajel, Ashish and Tey, Siok-Keen and Yeung, David and Cole, Theresa and Lewis, Clinton and Butler, Jason},
title = {ANZTCT consensus position statement on ruxolitinib in steroid‐refractory acute and chronic graft‐versus‐host disease},
journal = {Internal Medicine Journal},
year = {2023},
doi = {10.1111/imj.16255}
}
EUVIMED